NovaBridge CEO Fu Wei Buys Big Block of Options Amid Leadership Shake‑Up, Sending Confidence Signals to Investors

Insider Buying Spurs Optimism Amid Leadership Shake‑Up On June 29, 2026, founder‑CEO Fu Wei executed a sizable block of employee share options and restricted share units in a transaction that netted zero cash. Fu’s purchase of 725,140 options at a $0 exercise price, along with additional options vesting at $12 and $16 thresholds, signals strong confidence in the company’s valuation trajectory. By acquiring 1,010,100 restricted units that vest over two years, Fu is aligning his personal wealth with the long‑term success of NovaBridge, suggesting he believes the stock is poised for a significant rebound.

A Quiet Buy in a Volatile Market The trade came at a price of $1.95, a marginal 0.02 % drop from the previous close, and it generated no notable buzz on social media. This low‑profile move contrasts with the recent spike in institutional trading activity, including the June 22 acquisitions by Chief Business Development Officer Cao Sean Wuxiong. The juxtaposition of high‑level insider purchases against a backdrop of flat price action indicates that top executives are confident in the company’s fundamentals, even as the share price has slipped 14.85 % year‑to‑date.

Implications for Investors Fu’s commitment, coupled with the leadership transition to Dr. Srishti Gupta, bolsters confidence in NovaBridge’s clinical pipeline. The company’s assets—givastomig and VIS‑101—are approaching critical milestones that could unlock valuation upside. Investors may interpret the insider buys as a bullish signal, potentially offsetting the recent downward trend. However, the lack of immediate price impact suggests that market sentiment remains cautious, likely awaiting tangible progress from upcoming clinical trials or partnership announcements.

Future Outlook With a market cap under $190 million and a 52‑week low of $1.46, NovaBridge still sits on a steep upside curve. The strategic shift in leadership, coupled with the insider buying spree, positions the company to navigate the next phase of clinical development. For investors, the key will be to monitor trial outcomes and any new strategic alliances that could trigger a more pronounced market response, turning these insider signals into tangible stock appreciation.